Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells.
The cellular and subcellular events governing Ab production with specificity for self Ags are poorly understood. In this study we examined the role of cellular interactions and cytokines in regulating the production of anti-DNA topoisomerase I (topo I) Ab, a major autoantibody in patients with systemic sclerosis (SSc). Topo I-specific T cell clones derived from SSc subjects and healthy donors were cultured with autologous peripheral blood B cells. Anti-topo I Ab production was induced by five of seven topo I-specific T cell clones derived from SSc subjects, but by none of eight T cell clones generated from healthy controls. However, two of the T cell clones from healthy controls provided help to HLA-DR-matched SSc B cells to produce anti-topo I Ab. The analysis of cytokine mRNA expression revealed that the ability to promote anti-topo I autoantibody production was strictly correlated with IL-2 and IL-6 expression by the T cell clones. Kinetic studies showed that IL-2 was required throughout the culture period for maximal autoantibody production and that both MHC-TCR and CD40-CD40L interactions were essential during the early phase of the culture. IL-6 was important in the late phase. Th1 clones (producing IL-2, but no IL-6) and Th2 clones (producing IL-6, but no IL-2) synergically activated autologous B cells to produce anti-topo I Ab. These results indicate that T cell-dependent B cell activation resulting in anti-topo I autoantibody production requires a series of temporally defined cell contact and soluble stimuli.
Kuwana
M
M
Department of Medicine, University of Pittsburgh School of Medicine, PA 15261, USA.
Medsger
T A
TA
Wright
T M
TM
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001323:Autoantibodies / Q000096:biosynthesis*; D001324:Autoantigens / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism; D002999:Clone Cells; D016207:Cytokines / Q000145:classification / Q000502:physiology*; D004264:DNA Topoisomerases, Type I / Q000276:immunology*; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000502:physiology; D015850:Interleukin-6 / Q000276:immunology / Q000494:pharmacology; D008211:Lymphocyte Cooperation; D008565:Membrane Proteins / Q000097:blood / Q000502:physiology*; D012595:Scleroderma, Systemic / Q000276:immunology; D012995:Solubility; D018417:Th1 Cells / Q000276:immunology / Q000378:metabolism*; D018418:Th2 Cells / Q000276:immunology / Q000378:metabolism*; D000093242:Interleukin-6 Inhibitors
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D001324:Autoantigens; D016207:Cytokines; D004264:DNA Topoisomerases, Type I; D018984:Epitopes, T-Lymphocyte; D007376:Interleukin-2; D015850:Interleukin-6; D008565:Membrane Proteins; D000093242:Interleukin-6 Inhibitors